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dence from clinical studies concerning the relative effectiveness
of Fluad® and non-adjuvanted vaccines in the over 65 popula-
tion. Evidence concerning the impact of Fluad® on hospitalisa-
tion was taken from an observational study, other resource use
parameters and costs from the literature. The analysis was per-
formed from the payer perspective (direct medical costs).
RESULTS: Based on the increased protective efﬁcacy of Fluad®
compared to non-adjuvanted vaccines, we estimated a reduction
in cases of between 11.8% and 23.8% depending on the inﬂuenza
strain circulating in the community. Using these estimates, for an
attack rate of Inﬂuenza-like Illness of 5% and a discount rate of
3%, the incremental cost per life year gained (CLYG) ranged from
€3103 to €23,894. In situations where there is antigenic drift
(which occurs every 2–5 years), all vaccines are less effective.
However, the efﬁcacy of Fluad® falls by only 2%, whereas that
of non-adjuvanted vaccines falls by 22%. With antigenic drift,
the cost-effectiveness of Fluad® compared to non-adjuvanted vac-
cines is enhanced due to the better protective effect, and depend-
ing on the circulating strain, ranged from being cost saving to an
incremental CLYG of €5709. CONCLUSION: Compared to non-
adjuvanted vaccines, Fluad® is cost-effective. Since the estimated
cost per life year gained is within acceptable thresholds, Fluad®
should be used as the vaccine of choice in older people. * Fluad®
is registered under the trade name Gripguard® in France.
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OBJECTIVES: To evaluate the cost-effectiveness of three differ-
ent immunization strategies (1st: one time routine vaccination of
all adolescents aged 11 years [yr], 2nd: college freshmen aged 18
yr, and 3rd: college freshmen living in dormitories aged 18 yr)
with meningococcal polysaccharide (serogroups A, C, Y and W-
135) vaccine [MCV4] compared to no vaccination from a soci-
etal perspective. METHODS: A decision analysis model using
backward induction method was employed with parameter
values from published literature and HCUPnet (Health care Cost
and Utilization Project). All subjects were followed until they
reached 29 yr-old. Direct costs (vaccine, administration, hospi-
talization, outbreak control, and lifetime care) and indirect costs
(patient and health care workers time cost) were measured in
2005 US$. Effectiveness was measured as quality adjusted life
years [QALYs]. All costs and QALYs were discounted at 3% and
cost-effectiveness was measured as incremental cost per QALYs
gained [ICER]. Uncertainty was evaluated using multiple one-
way sensitivity analyses. RESULTS: All strategies yielded favor-
able ICERs ($16,746, $29,447, and $19,203 for 1st, 2nd, and
3rd strategy, respectively). The results were more favorable when
herd immunity was considered ($9916, $18,163, and $11,402
for 1st, 2nd, and 3rd strategy, respectively). All strategies were
highly sensitive to the duration of vaccine efﬁcacy and the dis-
count rate. A 50% decrease in these parameter values led to more
than a 100% change in ICERs. The herd immunity effect of
25%, 50%, and 75% lead approximately to 25%, 40%, and
50% change in ICERs. The model was sensitive to the disease
incidence rate, the risk for sequelae, and the vaccine cost, but
not to direct costs for treatment and the vaccine efﬁcacy. CON-
CLUSION: Three immunization strategies were cost-effective
compared to no vaccination using a societal threshold cut-off of
$50,000 per QALY. This analysis shows the opposite result to
previous U.S. ﬁndings. Further research is needed to explain
these discrepancies.
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OBJECTIVES: To examine the cost-effectiveness of PCV and to
determine if there is any long-term cost offset if it became a
routine vaccination for infants. METHODS: Two hypothetical
cohorts of 1000 infants (one vaccinated and one unvaccinated)
were followed over lifetime. A decision analytical model was
used to analyze the cost and cost-effectiveness of the vaccine
from a government’s perspective. The probabilities of events of
invasive pneumococcal diseases (IPD) and otitis media (OM)
were derived from published local or overseas data. Vaccine efﬁ-
cacy (mid-range) from overseas trials was used. Cost avoidance
arising from herd immunity was calculated based on overseas
published data. Cost of management of complications arising
from pneumococcal infections was estimated from a group of
hospitalized or outpatient cases from 2 large regional public hos-
pitals in Hong Kong. The costs associated with non-hospitalized
disease states were captured through interviews with a group of
identiﬁed GPs selected from different regions in Hong Kong. Vac-
cination programme costs included vaccine acquisition cost and
cost of administration. Productivity loss was assessed in terms of
extra care from family members, reduced earning ability and
early retirement due to disability, absenteeism, and premature
death. RESULTS: After a routine four-dose vaccination of infants
in their ﬁrst year of life, the PCV was estimated to have averted
566 cases of IPD and 2562 cases of OM. Using a discount rate
of 5% for all projections, the direct and indirect costs per life
year gained (CLYG) is HKD94,300 (USD12,090, 1USD =
7.8HKD) and HKD63,000 (USD8077) if no herd effect was
included. With herd immunity included, the direct and indirect
CLYG is reduced to HKD58,600 (USD7513) and HKD38,000
(USD4890) respectively. CONCLUSION: PCV appears to be
cost-saving by averting IPD and related complications and also
cost-effective due to herd immunity.
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OBJECTIVES: Evaluate the pharmacoeconomic impact of seven-
valent pneumococcal conjugate vaccine (Prevnar®) in a Cana-
dian population, accounting for herd immunity effects in
unvaccinated adults. METHODS: A cost-effectiveness analysis
was performed to compare costs and outcomes attributable to
invasive pneumococcal disease (IPD) and non-IPD in the periods
before (1998–2001) and after (2003–2005) the introduction of
Prevnar®. The main outcomes analyzed included total cases,
quality adjusted life years (QALY), and total cost for health
states bacteremia, meningitis, pneumonia, otitis media, myringo-
tomy, and death. Outcomes were based on real-world epidemi-
ology data from Calgary. Resource utilization was derived from
a Canadian Institute for Health Information database and, as
necessary, from the literature and expert opinion. All costs (in
2006 Canadian dollars) and outcomes were discounted by 3%.
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Analyses were conducted from both the societal and health care
system perspective. Sensitivity analyses were performed.
RESULTS: Reduction in disease outcomes, disease sequelae and
cost-of-illness by health state was observed in the time period
post-Prevnar®, across all age groups. The total cost of the vac-
cination program to the Canadian health care system (including
herd immunity effects), from a payer perspective amounted to
$74,682,790; this decreased to $46,197,274 from a societal per-
spective. The total number of illnesses avoided was 86,164. The
incremental cost-effectiveness ratio (ICER) was $28,551 and
$17,661 per additional QALY from the health system and soci-
etal perspectives, respectively. When herd immunity effects were
excluded from the analysis, the ICER increased to $166,560 and
$115,995 per QALY, respectively. Sensitivity analysis indicated
that total cost and ICER results were most sensitive to changes
in the epidemiology and cost of otitis media. However, these
changes did not considerably impact the results, indicating a
robust model. CONCLUSION: Consistent with previous ﬁnd-
ings, vaccination with Prevnar® is cost-effective. Administration
of Prevnar® results in a substantial reduction in pneumococcal
disease in vaccinated children and unvaccinated adults.
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OBJECTIVES: To investigate the cost effectiveness of gargling to
prevent upper respiratory tract infections (URI) from a societal
perspective. METHODS: The effectiveness of gargling for pre-
venting URI has been demonstrated in a randomized controlled
trial in which the participants recorded the frequency of gargling,
incidence and severity of URI and duration of daily medicine.
Costs of gargling, visiting physicians, medicine, and lost pro-
ductivity were considered. The cost of gargling was estimated as
the opportunity cost of the time required. The utility of severe
and moderate URI was also considered. Average costs and utility
during 60 days of observation in the trial were estimated as the
sum of the average daily cost and utility of the participants
remaining staying in the trial. The incremental cost effectiveness
ratio (ICER) of gargling when compared with the absence of gar-
gling was calculated, and bootstrap sampling generated an
acceptability curve. RESULTS: The estimated unit cost of gar-
gling was 49.2 yen. Assigned participants gargled 4.5 times per
day on average. The gargling group had higher costs and utility
than the group that did not gargle. The incremental cost and
effectiveness for 60 days were 4750 yen and 0.43 quality-
adjusted life days respectively. The gargling group required 8020
yen more for gargling, but saved 3270 yen by preventing URI
for 60 days. This showed that the ICER of gargling was 4.07
million yen/QALYs (34,400 US$/QALYs). The acceptability
curve showed 67.1% was less than 6 million yen/QALYs, and
88.7% less than 12 million yen/QALYs. CONCLUSION:
Although it can prevent URI, gargling is more costly than not
gargling because the cost of gargling exceeded the savings
derived from URI prevention. However, the ICER of gargling
was comparable with that of other widespread medical 
technologies.
PIN20
PHARMACOECONOMIC ANALYSIS OF SEVERE COMMUNITY-
ACQUIRED PNEUMONIA TREATMENT
Kulikov A, Krysanov I
Moscow Medical Academy, Moscow, Russia
OBJECTIVES: Selection of the most cost-effective treatment
regimen of severe community-acquired pneumonia. METHODS:
Direct medical expenditure on courses of treatment with lev-
oﬂoxacin and ceftriaxone were evaluated during this trial. “Cost
minimization” analysis was chosen as a pharmacoeconomic
method, and a “lost opportunities” index was calculated when
using less cost-effective drugs. RESULTS: Direct medical costs in
the group of patients who received levoﬂoxacin amounted to
16,097.99 rubles, and in the group of patients who were treated
with ceftriaxone they totaled 32,573.47 rubles per patient. They
were made up of levoﬂoxacin and ceftriaxone antibacterial drug
treatment costs and the costs of patients’ hospital stay. The cost
of the drug treatment course amounted to 3,997.99 rubles for
the ﬁrst group (levoﬂoxacin) and to 19,073.47 rubles for the
second group (ceftriaxone); the cost of hospital stay amounted
to 12,100 rubles and 13,500 rubles respectively. In the break-
down of expenditure on treatment of community-acquired pneu-
monia with levoﬂoxacin, patients’ hospital stay accounted for
75% of expenses, whereas drug treatment accounted for only
25% thereof; when treating with ceftriaxone, the expenditure on
patients’ hospital stay amounted to 40% and that on drug treat-
ment—to 60%. The “lost opportunities” index equaled one and
thus indicated that when using a more cost-effective drug (lev-
oﬂoxacin) for the treatment of one patient compared to a less
cost-effective drug (ceftriaxone) it is possible to theoretically
treat an additional patient, taking into account the difference in
the costs of treatment with the drugs compared, provided the
proﬁle of antibiotic resistance is congruent with that under the
conditions of the clinical study used herein. CONCLUSION:
Antibacterial treatment of severe community-acquired pneumo-
nia with levoﬂoxacin is more cost-effective, enabling the reduc-
tion of costs by 16,475 rubles per patient compared to treatment
with ceftriaxone owing to lower expenditure on drugs.
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OBJECTIVES: Complicated skin and skin structure infections
(cSSSIs) are a common complication among hospitalized patients.
There are limited national data on the costs of cSSSIs due to
Staphylococcus aureus, a common hospital-acquired pathogen.
METHODS: This retrospective cohort study used data from the
2004 Health care Cost and Utilization Project Nationwide Inpa-
tient Sample (HCUP-NIS). Patients with S. aureus cSSSIs were
identiﬁed based on ICD-9-CM diagnosis codes and compared to
patients without skin infections. Excess mortality, length of stay
(LOS), and costs were estimated for both groups. Multivariate
models (with log transformation) were used to adjust costs for
potential confounding factors, including age, gender, mortality,
hospital region, and comorbidity. RESULTS: We identiﬁed 55,585
hospitalized patients with cSSSIs due to S. aureus. The compari-
son cohort consisted of 7,618,776 patients without skin infec-
tions. The mortality rates were similar for the S. aureus cSSSI and
comparison cohorts (3.9% and 2.0%, respectively). For com-
